The Role of Blood Purification by Hemoadsorption as Adjunctive Treatment in Children With Septic Shock
Septic Shock, Multi Organ Failure
About this trial
This is an interventional treatment trial for Septic Shock focused on measuring Blood purification, Hemoperfusion, HA330, PELOD-2 score, PRISM-3 score
Eligibility Criteria
Inclusion Criteria:
Children were 30 days to 15 years of age, who required any dose of at least one vasopressor and one of following
- Pediatric Logistic Organ Dysfunction (PELOD)-2 score ≥ 10
- Pediatric Risk of Mortality (PRISM)-3 score ≥ 15
Exclusion Criteria:
- Patients receiving end-of-life support
- Patients who uncontrolled bleeding
Sites / Locations
- Faculty of Medicine, Chulalongkorn University
Arms of the Study
Arm 1
Arm 2
No Intervention
Active Comparator
The historical control group
The HA-treated group
The historical control group was composed of patients treated septic shock between May 2019 and May 2021. They was received routine treatment for septic shock including intravenous fluid resuscitation, antibiotics, removal of source of infection and inotropic drugs within 6 hours after the diagnosis of sepsis.
The HA-treated group will be enrolled between July 2021 and May 2022. This group included children with sepsis, who were admitted to our PICU during the study period. All children initially received routine treatment for septic shock as the historical control group. An HA330 disposable hemoperfusion cartridge (HA330; Jafron, Zhuhai City, China) was used with a continuous renal replacement therapy (CRRT) machine (Aquarius® or Primaflex®) in this intervention group.